New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants
Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29 patients (17 patients received dabigatran and 12...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2288 |
| _version_ | 1797232065454800896 |
|---|---|
| author | K. B. Mirzaev D. V. Ivashchenko I. V. Volodin E. A. Grishina K. A. Akmalova A. A. Kachanova A. I. Skripka R. M. Minnigulov T. E. Morozova O. A. Baturina A. N. Levanov T. V. Shelekhova A. I. Kalinkin D. A. Napalkov A. A. Sokolova D. A. Andreev I. N. Sychev P. O. Bochkov D. A. Sychev |
| author_facet | K. B. Mirzaev D. V. Ivashchenko I. V. Volodin E. A. Grishina K. A. Akmalova A. A. Kachanova A. I. Skripka R. M. Minnigulov T. E. Morozova O. A. Baturina A. N. Levanov T. V. Shelekhova A. I. Kalinkin D. A. Napalkov A. A. Sokolova D. A. Andreev I. N. Sychev P. O. Bochkov D. A. Sychev |
| author_sort | K. B. Mirzaev |
| collection | DOAJ |
| description | Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29 patients (17 patients received dabigatran and 12 –rivaroxaban), who had hemorrhagic complications during taking direct oral anticoagulants. To find new pharmacogenetic biomarkers of bleeding risk, a next generation sequencing (NGS) was performed for selected candidate genes.Results. Among the patients with bleeding who received dabigatran, 13 variants of the nucleotide sequence showed statistically significant deviation from the population values: 11 in the CES1 gene and 2 in the ABCB1 gene. Among the patients with bleeding who received rivaroxaban, 7 variants of nucleotide sequence showed significant deviation: 4 in the ABCG2 gene, 2 in the CYP3A4 gene, and 1 in the ABCB1 gene.Conclusion. The identified in this study polymorphisms of candidate genes ABCB1, ABCG2, CES1, CYP3A4 were associated with the risk of bleeding in patients taking rivaroxaban and dabigatran. It makes an important contribution to the pharmacogenetics of direct oral anticoagulants and require additional assessment of clinical significance in further studies. |
| first_indexed | 2024-03-08T14:00:42Z |
| format | Article |
| id | doaj.art-060e30356f7741b38e1ef181c3cd5e48 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:54:21Z |
| publishDate | 2020-11-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-060e30356f7741b38e1ef181c3cd5e482024-04-01T07:43:40ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-11-0116567067710.20996/1819-6446-2020-10-051786New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral AnticoagulantsK. B. Mirzaev0D. V. Ivashchenko1I. V. Volodin2E. A. Grishina3K. A. Akmalova4A. A. Kachanova5A. I. Skripka6R. M. Minnigulov7T. E. Morozova8O. A. Baturina9A. N. Levanov10T. V. Shelekhova11A. I. Kalinkin12D. A. Napalkov13A. A. Sokolova14D. A. Andreev15I. N. Sychev16P. O. Bochkov17D. A. Sychev18Russian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional Education; Research Centre for Medical GeneticsRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Saratov State Medical University named after V.I. RazumovskySaratov State Medical University named after V.I. RazumovskyResearch Centre for Medical GeneticsI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationAim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29 patients (17 patients received dabigatran and 12 –rivaroxaban), who had hemorrhagic complications during taking direct oral anticoagulants. To find new pharmacogenetic biomarkers of bleeding risk, a next generation sequencing (NGS) was performed for selected candidate genes.Results. Among the patients with bleeding who received dabigatran, 13 variants of the nucleotide sequence showed statistically significant deviation from the population values: 11 in the CES1 gene and 2 in the ABCB1 gene. Among the patients with bleeding who received rivaroxaban, 7 variants of nucleotide sequence showed significant deviation: 4 in the ABCG2 gene, 2 in the CYP3A4 gene, and 1 in the ABCB1 gene.Conclusion. The identified in this study polymorphisms of candidate genes ABCB1, ABCG2, CES1, CYP3A4 were associated with the risk of bleeding in patients taking rivaroxaban and dabigatran. It makes an important contribution to the pharmacogenetics of direct oral anticoagulants and require additional assessment of clinical significance in further studies.https://www.rpcardio.online/jour/article/view/2288dabigatranrivaroxabanpharmacogeneticsdirect oral anticoagulantssequencingpersonalized medicine |
| spellingShingle | K. B. Mirzaev D. V. Ivashchenko I. V. Volodin E. A. Grishina K. A. Akmalova A. A. Kachanova A. I. Skripka R. M. Minnigulov T. E. Morozova O. A. Baturina A. N. Levanov T. V. Shelekhova A. I. Kalinkin D. A. Napalkov A. A. Sokolova D. A. Andreev I. N. Sychev P. O. Bochkov D. A. Sychev New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants Рациональная фармакотерапия в кардиологии dabigatran rivaroxaban pharmacogenetics direct oral anticoagulants sequencing personalized medicine |
| title | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants |
| title_full | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants |
| title_fullStr | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants |
| title_full_unstemmed | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants |
| title_short | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants |
| title_sort | new pharmacogenetic markers to predict the risk of bleeding during taking of direct oral anticoagulants |
| topic | dabigatran rivaroxaban pharmacogenetics direct oral anticoagulants sequencing personalized medicine |
| url | https://www.rpcardio.online/jour/article/view/2288 |
| work_keys_str_mv | AT kbmirzaev newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT dvivashchenko newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT ivvolodin newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT eagrishina newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT kaakmalova newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT aakachanova newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT aiskripka newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT rmminnigulov newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT temorozova newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT oabaturina newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT anlevanov newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT tvshelekhova newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT aikalinkin newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT danapalkov newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT aasokolova newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT daandreev newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT insychev newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT pobochkov newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants AT dasychev newpharmacogeneticmarkerstopredicttheriskofbleedingduringtakingofdirectoralanticoagulants |